Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2007 1
2013 2
2014 1
2015 2
2016 4
2017 1
2018 2
2019 3
2020 4
2021 5
2022 1
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. Hong D, et al. Among authors: zhou t. Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272. Sci Transl Med. 2015. PMID: 26582900 Free PMC article. Clinical Trial.
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Lin TL, Chim CS, Qi M, Wang J, Lu X, Song Y, Jia B, Yang X, Liu W, Zhou T, Yin L, Li Y, Zhang R, Hou J, Wang J. Fu W, et al. Among authors: zhou t. Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):446-455.e4. doi: 10.1016/j.clml.2023.02.009. Epub 2023 Mar 4. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37024420 Free article. Clinical Trial.
Passive microfluidic devices for cell separation.
Zhang T, Di Carlo D, Lim CT, Zhou T, Tian G, Tang T, Shen AQ, Li W, Li M, Yang Y, Goda K, Yan R, Lei C, Hosokawa Y, Yalikun Y. Zhang T, et al. Among authors: zhou t. Biotechnol Adv. 2024 Mar-Apr;71:108317. doi: 10.1016/j.biotechadv.2024.108317. Epub 2024 Jan 12. Biotechnol Adv. 2024. PMID: 38220118 Review.
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye BH, Frank DA, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B, Verma A. Shastri A, et al. Among authors: zhou t. J Clin Invest. 2018 Dec 3;128(12):5479-5488. doi: 10.1172/JCI120156. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30252677 Free PMC article.
An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma.
Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, MacLeod AR, Morrison SL, Herschman HR. Xu S, et al. Among authors: zhou t. Cancer Res. 2019 May 15;79(10):2748-2760. doi: 10.1158/0008-5472.CAN-18-2799. Epub 2019 Mar 18. Cancer Res. 2019. PMID: 30885978 Free PMC article.
Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
Zhang J, Fu L, Shen B, Liu Y, Wang W, Cai X, Kong L, Yan Y, Meng R, Zhang Z, Chen YP, Liu Q, Wan ZK, Zhou T, Wang X, Gavine P, Del Rosario A, Ahn K, Philippar U, Attar R, Yang J, Xu Y, Edwards JP, Dai X. Zhang J, et al. Among authors: zhou t. Cell Chem Biol. 2020 Dec 17;27(12):1500-1509.e13. doi: 10.1016/j.chembiol.2020.08.010. Epub 2020 Sep 3. Cell Chem Biol. 2020. PMID: 32888499 Free article.
32 results